Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 214,200 shares, a growth of 604.6% from the March 31st total of 30,400 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is currently 0.2 days.

Sonoma Pharmaceuticals Price Performance

Shares of SNOA remained flat at $0.16 during trading hours on Friday. 108,630 shares of the company were exchanged, compared to its average volume of 362,434. The company’s 50 day moving average is $0.15 and its 200-day moving average is $0.21. Sonoma Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $1.52.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Thursday, February 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. Sonoma Pharmaceuticals had a negative return on equity of 58.93% and a negative net margin of 41.24%. The company had revenue of $3.14 million during the quarter. On average, equities research analysts expect that Sonoma Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.